Search bioRxiv⌕ Search

bioRxiv · 10.64898/2025.12.18.694904

Novel Highly Homeostatic B Cells induced by Immunomodulatory Oligonucleotide IMT504

Abstract

Cellular homeostasis depends on endoplasmic reticulum (ER) function and is highly sensitive to ER stress typically triggered by protein-folding overload. To restore balance, eukaryotic cells engage the unfolded protein response (UPR), a network of signaling pathways that enhances resistance to stress by upregulating chaperones, reducing global translation, and promoting degradation of unfolded proteins via autophagy. Additional stress-sensing pathways, including the NRF2 antioxidant response and the AMPK energy-sensing axis, converge to reinforce cellular homeostasis. In pathological conditions, reinforcing immune homeostasis constitutes a promising therapeutic strategy. Among emerging pharmacological agents that activate endogenous protective pathways, the synthetic immunomodulatory oligonucleotide IMT504 has shown favorable pharmacokinetics and stability in preclinical models, although its mechanisms of action remain unclear. Using purified human CD19 B cells, we investigated the cellular, molecular, and transcriptional responses to IMT504 stimulation, to uncover new insights into its mode of action and broader implications for immune-mediated homeostasis. We discovered that incubation of CD19CD27- B cells with IMT504 directly induces a-previously unreported-subpopulation of human B cells, which we termed B homeostatic cells (Bhom). These Bhom cells display a distinctive phenotype (CD27-CD24CD38CD138-MUC1) and upregulate genes associated with mitochondrial metabolism, proteostasis, antioxidant defense, and survival. Promoter analysis of the most highly upregulated genes revealed an Invariant Gene Transcriptional Regulator (IGTR) signature with binding motifs for MYC, CREB1, CTCF, EP300 and NRF1/NRF2, suggesting a coordinated transcriptional control of the involved homeostatic programs. Network analysis linked NRF1 to SIRT1/PGC1 metabolic axis and NRF2 to IGTR-regulated factors. Furthermore, we found that IMT504 binds ATP-citrate lyase (ACLY), an endogenous repressor of AMPK, indicating that IMT504 may activate AMPK-dependent autophagy and downstream NRF1/NRF2 signaling. Altogether, these findings identify Bhom cells as a novel B-cell subset that embodies homeostatic features and reveal IMT504 as a potent inducer of B-cell-mediated homeostasis through AMPK-driven transcriptional reprogramming. This mechanism strongly supports IMT504 as a promising candidate for immune-modulatory therapies aimed at restoring immune homeostasis. SIGNIFICANCE STATEMENTThe discovery of a novel B-cell subset, termed B homeostatic cells (Bhom), reveals a previously unrecognized axis of immune response. Incubation of human CD19CD27-B cells with the immunomodulatory oligonucleotide IMT504 directly induces Bhom cells. Its differentiation engages a conserved transcriptional network centered on AMPK-NRF1/NRF2 signaling, highlighting a potential therapeutic pathway to restore or enhance immune homeostasis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

RODRIGUEZ, J. M., Elias, F., Oberholzer, M. V., Zylberberg, C., Flo, J. M., Lopez, R. A., Bridges, A. J., Jerusalinsky, D. A., zorzopulos, J.. 2025-12-22. Novel Highly Homeostatic B Cells induced by Immunomodulatory Oligonucleotide IMT504. https://doi.org/10.64898/2025.12.18.694904

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗